Risk stratification of severe infections after remission induction therapy in idiopathic inflammatory myopathy: a multicentre myko study

Clicks: 9
ID: 337591
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #327 of 335 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 335 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: To identify baseline predictors and develop a clinical risk stratification model for severe infections (SI) in patients with idiopathic inflammatory myopathy (IIM) after remission induction therapy. METHODS: We enrolled patients diagnosed with IIM between 1991 and 2024 from three Japanese centres participating in the multicentre Idiopathic Inflammatory Myopathy and Anti-synthetase Syndrome (MYKO) cohort. SI was defined as an infection requiring intravenous antibiotics or hospitalisation. We explored the risk factors for predicting SI in patients with IIM by comparing the initial demographic, clinical, laboratory, and treatments between the SI and non-SI groups. RESULTS: Among 349 patients with IIM, 14.6% of patients developed SIs after remission induction therapy over a median follow-up of 4.7 years. Patients who developed SI exhibited significantly lower baseline albumin levels, and significantly higher baseline C-reactive protein (CRP), lactate dehydrogenase, and surfactant protein (SP-D) levels than those without SI. Multivariate logistic regression analysis demonstrated that elevated CRP and SP-D levels were independently associated with SI. Serum CRP levels remained significantly higher in the SI group than in the non-SI group over the two-year period after immunosuppressive therapy, and the serum SP-D levels tended to be higher in the SI group. The 10-year SI rate was significantly different among patients with IIM stratified by the number of risk factors, defined as CRP ≥ 0.8 mg/dL and SP-D ≥ 96.2 ng/mL. CONCLUSIONS: This model, which consists of CRP ≥ 0.8 mg/dL, SP-D ≥ 96.2 ng/mL, is useful for clinical risk stratification of SI after remission induction therapy in IIM.
Reference Key
openalex_W7224082312 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Mahiro Yamamoto, Shogo Matsuda, Katsumasa Oe, Chifumi Akiyama, Takayasu Suzuka, Ran Nakashima, Hideaki Tsuji, Tsuneo Sasai, Yasuhiro Nohda, Tsuneyasu Yoshida, Yoichi Nakayama, Yuto Nakakubo, Atsubumi Ogawa, Kazuma Yoshida, Keisuke Hirobe, Yuki Aitani, Yudai Koshida, Hirofumi Miyake, Tohru Takeuchi, Takuya Kotani
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag599
URL
https://doi.org/10.1093/rheumatology/keag599
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.